Life Technologies Quantstudio 7 Flex Real-Time PCR (qPCR) Service Agreement (“AB Assurance” or equal plan), Base Year plus two options

The FDA Office of Acquisition and Grant Services is conducting a market survey on behalf of the National Center for Toxicological Research (NCTR) regarding preventative maintenance and unlimited repair service contracts for a Life Technologies Quantstudio 7 Flex Real-Time PCR instrument, with capability statements due by May 18, 2026. This is a sources-sought announcement for information only; no contract will be awarded and no reimbursement will be made for response costs.

Performance occurs at NCTR's facility in Jefferson, Arkansas. The service period runs for a base year (August 15, 2026 through August 14, 2027) plus two optional years. Required services include all parts, labor, and travel for preventative maintenance and unlimited corrective repairs; one preventative maintenance inspection annually covering the qPCR and accessory blocks (Fast 96-well, 384-well, and TaqMan Array Cards); calibration and temperature verification; guaranteed two-business-day priority response time; service availability 8:00 a.m. to 5:00 p.m. Monday through Friday excluding holidays; priority technical support via telephone and email; remote support capability; and work performed by OEM-trained and certified technicians per OEM specifications using new OEM parts.

Respondents should submit capability statements to suzanne.martella@fda.hhs.gov including company information, SAM unique entity ID, past performance data (within three years), technical capability documentation, estimated response times, GSA Schedule or government-wide contract information if applicable, and warranty, payment terms, and informational pricing. The announcement targets NAICS 811210 (Other Electronic and Precision Equipment Repair and Maintenance) with a size standard of $34 million, though all interested parties may respond.